Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Olema PharmaceuticalsOLMA | Open-market sale | 03/03–03/04 | 03/05 | 40,000 sh3 trades | $23.79avg. | $951,502.52 | −100.0% | |
Cyrus HarmonDirector | Olema PharmaceuticalsOLMA | Open-market sale | 01/20 | 01/21 | 10,000 sh | $26.88 | $268,800 | −1.4% |
Cyrus HarmonDirector | Olema PharmaceuticalsOLMA | Open-market sale | 01/14 | 01/16 | 3,489 sh | $29.12 | $101,599.68 | −0.5% |
Olema PharmaceuticalsOLMA | Open-market sale | 01/13–01/15 | 01/15 | 103,822 sh2 trades | $28.70avg. | $2,980,054.22 | −42.6% | |
Olema PharmaceuticalsOLMA | Open-market sale | 01/12–01/14 | 01/14 | 110,000 sh5 trades | $28.25avg. | $3,107,229.17 | No record | |
Cyrus HarmonDirector | Olema PharmaceuticalsOLMA | Open-market sale | 25/12/22 | 25/12/29 | 2,881 sh | $28.53 | $82,194.93 | −0.4% |
Olema PharmaceuticalsOLMA | Open-market sale | 25/12/19–25/12/23 | 25/12/23 | 269,509 sh4 trades | $27.94avg. | $7,530,147.84 | −98.4% | |
Olema PharmaceuticalsOLMA | Open-market sale | 25/12/19 | 25/12/23 | 264,800 sh3 trades | $29.73avg. | $7,873,109.28 | −100.0% | |
Olema PharmaceuticalsOLMA | Open-market sale | 25/12/19 | 25/12/23 | 51,000 sh3 trades | $30.46avg. | $1,553,543.54 | −8.5% | |
Olema PharmaceuticalsOLMA | Open-market sale | 25/09/16–25/09/18 | 25/09/18 | 25,000 sh4 trades | $8.19avg. | $204,840.64 | No record | |
Bain Capital Life Sciences Investors10% Owner | Olema PharmaceuticalsOLMA | Open-market buy | 25/01/08 | 25/01/13 | 300,000 sh | $5.76 | $1,728,000 | +4.0% |
Olema PharmaceuticalsOLMA | Open-market buy | 25/01/08 | 25/01/13 | 300,000 sh | $5.76 | $1,728,000 | +4.0% | |
Bain Capital Life Sciences Fund IV10% Owner | Olema PharmaceuticalsOLMA | Open-market buy | 25/01/08 | 25/01/13 | 300,000 sh | $5.76 | $1,728,000 | +4.0% |
Olema PharmaceuticalsOLMA | Open-market buy | 25/01/08 | 25/01/13 | 300,000 sh | $5.76 | $1,728,000 | +4.0% | |
Olema PharmaceuticalsOLMA | Open-market buy | 25/01/08 | 25/01/13 | 300,000 sh | $5.76 | $1,728,000 | +4.0% | |
G. Walmsley GrahamDirector | Olema PharmaceuticalsOLMA | Open-market buyAmendment | 24/12/13 | 24/12/18 | 700,761 sh | $6.75 | $4,730,136.75 | No record |
G. Walmsley GrahamDirector | Olema PharmaceuticalsOLMA | Open-market saleAmendment | 24/12/13 | 24/12/18 | 700,761 sh | $6.75 | $4,730,136.75 | −100.0% |
G. Walmsley GrahamDirector | Olema PharmaceuticalsOLMA | Open-market buy | 24/12/17 | 24/12/17 | 700,761 sh | $6.75 | $4,730,136.75 | −33.2% |
G. Walmsley GrahamDirector | Olema PharmaceuticalsOLMA | Open-market sale | 24/12/17 | 24/12/17 | 700,761 sh | $6.75 | $4,730,136.75 | −100.0% |
Olema PharmaceuticalsOLMA | Open-market sale | 24/12/10–24/12/11 | 24/12/11 | 35,159 sh3 trades | $9.01avg. | $316,703.45 | −6.1% |